What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?

During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Mikkael Sekeres,...

Visual abstract: Roxadustat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome: Open-label, Dose-selection, Lead-in Stage of a Phase 3 Study

Visual abstract: Roxadustat...

The IPSS-Molecular, a new risk stratification for patients with MDS

Myelodysplastic syndromes (MDS) are a heterogeneous group of rare blood cancers and therefore have varying clinical outcomes. Some...

Should novel agents be used prior to transplant in MDS-EB1/2?

During the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the MDS Hub was...

Safety and efficacy of enasidenib in IDH2-mutated myelodysplastic syndrome

Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor approved by the U.S. Food and Drug Administration in 2017 for...

A personalized prognostic prediction model based on genomic features in patients with MDS

Myelodysplastic syndromes (MDS) have a disease spectrum ranging from indolent conditions to rapidly...

Double minute chromosomes associated with rare cytogenetic abnormalities and poor prognosis in MDS and AML

Double minute chromosomes (DM) are circular extrachromosomal DNA fragments, which can...

Prevalence and impact of PPM1D mutations in patients with MDS and del(5q)

Mutations in the PPM1D gene drive clonal hematopoiesis and occur in various malignancies.

Prevalence and impact of PPM1D mutations in patients with MDS and del(5q)

Mutations in the PPM1D gene drive clonal hematopoiesis and occur in various malignancies.

Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis

The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines,...

What is new for MDS with del(5q)?

During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...

Updated ESMO clinical practice guidelines for diagnosis, treatment, and follow-up of MDS

The European Society for Medical Oncology (ESMO) Guidelines Committee issued an update of their Clinical...